Search
Close this search box.

Slovenian Tourist Board published an article exploring the highlights in Slovenia 2026

Slovenia highlights 2026 LJUBLJANA, Slovenia, Dec. 10, 2025 (GLOBE NEWSWIRE) — In 2026, Slovenia invites travelers – and storytellers – to explore a year rich in cultural milestones, outdoor adventures and experiences that redefine slow, meaningful travel. With the Slovenian Tourist Board at the helm, the country showcases everything from

Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season

Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season VICTORIA, Seychelles, Dec. 09, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), has released new data showing unprecedented growth in global demand for tokenized US equities during the recent earnings season. From mid-October to

Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy

Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy Leave a reply RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its vision for telco-first,

Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy

RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its vision for telco-first, cloud-native, AI-by-design networks. This transformation follows the company’s recent recapitalization and aligns with a refreshed product strategy focused on mobile core, AI-enabled

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks Leave a reply REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43%

About Us

Promoting revolutionary values and uniting movements for South Africa’s economic freedom.

Newsletter

Enter your email address below to subscribe to my newsletter